Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. BioPharmX Corporation (BPMX) Message Board

BioPharmX Presents BPX-01 Topical Minocycline Gel

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 223
Posted On: 11/10/2016 9:09:08 AM
Avatar
Posted By: Whos_Who
BioPharmX Presents BPX-01 Topical Minocycline Gel Acne Data at SDEF's 17th Annual Las Vegas Dermatology Seminar

MENLO PARK, Calif., Nov. 10, 2016 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, will present results from two clinical studies comparing oral and topical minocycline during a poster presentation at the Skin Disease Education Foundation's 17th Annual Las Vegas Dermatology Seminar today through Saturday.

Presentation Details:

Title: "BPX-01 Minocycline 1% topical Gel for the Treatment of Acne Vulgaris"
Author: AnnaMarie Daniels
Location: The Cosmopolitan Las Vegas, 4th Floor, Belmont 4-8 Ballroom
Dates: November 10-12, 2016

The poster will show that daily application of BPX-01 one percent topical minocycline gel for four weeks was well tolerated and resulted in a statistically significant reduction in P. acnes bacteria in the per protocol population with no detectable minocycline in the plasma. Prior observations indicate that BPX-01 was effectively delivered into the pilosebaceous units, which was confirmed clinically by a reduction in P. acnes counts without evidence of systemic exposure. Conversely, our second study indicated that daily administration of oral minocycline for the same period of time resulted in high circulating levels of minocycline. These two studies suggest that BPX-01 topical minocycline may have a favorable pharmacokinetic advantage over oral minocycline for the treatment of acne vulgaris. A confirmatory phase 2b clinical study to support this observation is in progress.


(0)
(0)




BioPharmX Corporation (BPMX) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us